Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.

Anticancer research - 1 Jun 2013

Sasaki Takashi, Isayama Hiroyuki, Nakai Yousuke, Takahara Naminatsu, Satoh Yumiko, Takai Daiya, Kogure Hirofumi, Yamamoto Natsuyo, Hirano Kenji, Tada Minoru, Yatomi Yutaka, Koike Kazuhiko

Abstract excerpt

AIM: To evaluate the treatment outcomes of irinotecan monotherapy for patients with advanced biliary tract cancer refractory to gemcitabine, cisplatin, and oral fluoropyrimidine. PATIENTS AND METHODS: Irinotecan (100 mg/m(2)) was administered intravenously on days 1, 8, and 15, repeated every four weeks. RESULTS: Thirteen patients were enrolled. The dose intensity was only 55.0%. The response rate and disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biliary Tract Neoplasms
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Pilot Projects

Share to Salvage Therapy

Share to Survival Rate

Share to Topoisomerase I Inhibitors

Source

Identifiers

PMID: 23749917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.PMID 23749917Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Systemic treatment options for advanced biliary tract carcinoma.Semantic proximity Read ↗

Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity Read ↗

New Treatment Options for Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations.Semantic proximity Read ↗

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Semantic proximity Read ↗

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Semantic proximity Read ↗

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.Semantic proximity Read ↗

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.Semantic proximity Read ↗

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Semantic proximity Read ↗

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.